HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $1245 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.3%

Neg 0% Neu 89.3% Pos 0%

HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $1245 price target.